Who makes Ropivacaine 0.2%-NaCl 0.9% Injectable Solution?

Ropivacaine 0.2%-NaCl 0.9% Injectable Solution is developed by Virginia Commonwealth University.

What development phase is Ropivacaine 0.2%-NaCl 0.9% Injectable Solution in?

Ropivacaine 0.2%-NaCl 0.9% Injectable Solution is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ropivacaine 0.2%-NaCl 0.9% Injectable Solution

Virginia Commonwealth University · FDA-approved active Small molecule Quality 5/100

At a glance

Generic name	Ropivacaine 0.2%-NaCl 0.9% Injectable Solution
Sponsor	Virginia Commonwealth University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Erector Spinae Plane Block for Acute Low Back Pain (NA)
SII Levels Following PENG Block in Hip Arthroplasty (NA)
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
NLR and PLR Levels Following PENG Block in Hip Arthroplasty (PHASE4)
Dexamethasone for PENG Block in Total Hip Arthroplasty (PHASE4)
NLR and PLR Levels Following IPACK Block in Knee Arthroplasty (PHASE4)
Comparison Ultrasound-Guided Adductor Canal Block and Surgeon-Performed Block for Pain Management After Total Knee Arthroplasty (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ropivacaine 0.2%-NaCl 0.9% Injectable Solution CI brief — competitive landscape report
Ropivacaine 0.2%-NaCl 0.9% Injectable Solution updates RSS · CI watch RSS
Virginia Commonwealth University portfolio CI